Yes when there are no safety issues and PROS like this and that about PBT2 - those are the perfect applications for an accelerated approval. Human testing with no safety issues should make the decision easy- require post approval study.
- Forums
- ASX - By Stock
- ATH
- SRPT Duchenne Drug trial hits 5 year mark
ATH
alterity therapeutics limited
Add to My Watchlist
6.67%
!
1.4¢

SRPT Duchenne Drug trial hits 5 year mark, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $138.1M |
Open | High | Low | Value | Volume |
1.4¢ | 1.4¢ | 1.4¢ | $10.85K | 775.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 7479968 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 16767291 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 7302465 | 0.014 |
28 | 20018703 | 0.013 |
31 | 13132007 | 0.012 |
20 | 13597532 | 0.011 |
35 | 18299059 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 14682291 | 13 |
0.016 | 5160605 | 11 |
0.017 | 7563023 | 11 |
0.018 | 11579020 | 23 |
0.019 | 15047176 | 11 |
Last trade - 10.10am 30/07/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |